Healthcare / Medical Instruments & SuppliesUpdated 2026-05-10 22:07 UTC

HBIO stock hub

Harvard Bioscience, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HBIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

31.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

HBIO

In the news

Latest news · HBIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E36.3

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-147.1

P25 -105.6P50 -46.5P75 -3.1

ROIC3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HBIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

233

Groups with data

Currency

USD

Showing 233 of 233 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001123494
Company name	Harvard Bioscience, Inc.
Country	United States
Country code	US
Cusip	416906204
Employees	339
Employees Change	-16%
Employees Change Percent	-4.51
Enterprise value	$66.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Medical Instruments & Supplies
IPO Date	2000-12-07
Isin	US4169062043
Last refreshed	2026-05-10
Market cap	$31.1M
Market cap category	Nano-Cap
Price	$6.9
Price currency	USD
Rev Per Employee	255,309.73x
Sector	Healthcare
Sic	3826
Symbol	HBIO
Website	https://www.harvardbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-182.33%
EV Sales Forward	0.74x
EV/EBIT	44.57x
EV/EBITDA	8.97x
EV/FCF	12.2x
EV/Sales	0.77x
FCF yield	17.59%
Forward P/E	36.29x
P/B ratio	2.25x
P/S ratio	0.36x
PS Forward	0.34x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	1.73%
EBITDA Margin	8.6%
FCF margin	6.32%
Gross margin	57.67%
Gross Profit	$49.9M
Gross Profit Growth	-8.94%
Gross Profit Growth Q	0.84%
Gross Profit Growth3 Y	-7.12%
Gross Profit Growth5 Y	-2.97%
Net Income	$-56.7M
Net Income Growth Years	0%
Pretax Margin	-66.3%
Profit Margin	-65.51%
Profit Per Employee	$-167,257
ROA	0.91
Roa5y	-0.18
ROCE	2.58
ROE	-147.1
Roe5y	-36.52
ROIC	3.01

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-13.14%
Cagr15y	-11.18%
Cagr1y	129.96%
Cagr20y	-7.78%
Cagr3y	-51.8%
Cagr5y	-37.69%
EPS Growth Years	0
FCF Growth5 Y	-7.73%
OCF Growth	367.29%
OCF Growth10 Y	25.31%
OCF Growth3 Y	80.09%
OCF Growth5 Y	-6.33%
Revenue Growth	-8.06x
Revenue Growth Q	-3.34x
Revenue Growth Years	0x
Revenue Growth3 Y	-8.6x
Revenue Growth5 Y	-3.25x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.84
Assets	$80.1M
Cash	$8.6M
Current Assets	$48.2M
Current Liabilities	$22M
Debt	$44.3M
Debt EBITDA	$4.53
Debt Equity	$3.22
Debt FCF	$8.09
Equity	$13.7M
Interest Coverage	0.3
Liabilities	$66.3M
Long Term Assets	$31.8M
Long Term Liabilities	$44.4M
Net Cash	$-35.7M
Net Cash By Market Cap	$-115
Net Debt EBITDA	$4.79
Net Debt Equity	$2.6
Net Debt FCF	$6.52
Tangible Book Value	$-3.5M
Tangible Book Value Per Share	$-0.77
WACC	10.47

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.2
Inventory Turnover	1.66
Net Working Capital	$19.2M
Quick ratio	1.12
Working Capital	$26.3M
Working Capital Turnover	$10.54

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.96%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-75.55%
1Y total return	129.83%
200-day SMA	5.58
3Y total return	-88.81%
50-day SMA	5.68
50-day SMA vs 200-day SMA	50over200
5Y total return	-90.61%
All Time High	145
All Time High Change	-95.24%
All Time High Date	2001-09-04
All Time Low	2.81
All Time Low Change	145.11%
All Time Low Date	2025-05-28
ATR	0.48
Beta	1.57
Beta1y	2.45
Beta2y	2.19
Ch YTD	3.1
High	7.13
High52	9.46
High52 Date	2025-05-29
High52ch	-27.1%
Low	6.79
Low52	2.81
Low52 Date	2025-05-28
Low52ch	145.11%
Ma50ch	21.37%
Price vs 200-day SMA	23.61%
RSI	59.49
RSI Monthly	36.2
RSI Weekly	56.26
Sharpe ratio	1.08x
Sortino ratio	2.84
Total Return	-1.96%
Tr YTD	3.1
Tr15y	-83.12%
Tr1m	27.69%
Tr1w	8.41%
Tr3m	39.24%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.03
Earnings Revenue Estimate	21,200,000x
Earnings Revenue Estimate Growth	-2.64x
Operating Income	$1.5M
Operating Income Growth Q	624.4
Operating Income Growth5 Y	-7.85
Operating margin	1.73
Price target	$18
Price Target Change	$161

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,532,059%
Float Percent	78.31%
Net Borrowing	2,650,000
Shares Insiders	6.45%
Shares Institutions	35.27%
Shares Out	4,510,217
Shares Qo Q	0.1%
Shares Yo Y	1.96%
Short Float	6.89%
Short Ratio	3.05
Short Shares	5.4

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$3.6M
Average Volume	50,808.55x
Bv Per Share	3.07
CAPEX	$-1.3M
Ch10y	-75.55
Ch15y	-87.21
Ch1m	27.69
Ch1w	8.41
Ch1y	129.8
Ch20y	-85.01
Ch3m	39.24
Ch3y	-88.81
Ch5y	-90.61
Ch6m	26.96
Change	1.55%
Change From Open	-0.07
Close	6.79
Days Gap	1.62
Depreciation Amortization	5,945,000
Dollar Volume	98,653.7
Earnings Date	2026-05-12
Earnings Time	bmo
EBIT	$1.5M
EBITDA	$7.4M
EPS	$-12.8
F Score	5
FCF	$5.5M
FCF EV Yield	8.19x
FCF Per Share	$1.21
Financing CF	-1,291,000
Fiscal Year End	December
Founded	1,901
Goodwill	9,559,000
Income Tax	$-686,000
Investing CF	-1,863,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-12
Last Report Date	2025-12-31
Last Split Date	2026-03-16
Last Split Type	Reverse
Last10k Filing Date	2026-03-13
Ma150	5.84
Ma150ch	18.17%
Ma20	6.37
Ma20ch	8.31%
Net CF	4,506,000
Next Earnings Date	2026-05-12
Open	6.9
Optionable	Yes
P FCF Ratio	5.68
P OCF Ratio	4.62
Position In Range	30.88
Post Close	6.9
Postmarket Change Percent	1.52
Postmarket Price	$7
Ppne	11,959,000
Price Date	2026-05-08
Price EBITDA	$4.18
Relative Volume	0.28x
Revenue	86,550,000x
SBC By Revenue	2.14x
Share Based Comp	1,855,000
Tax By Revenue	-0.79x
Tr20y	-80.22%
Tr6m	26.96%
Us State	Massachusetts
Volume	14,308
Z Score	-1.95

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does HBIO pay a dividend?

Capital-return profile for this ticker.

Performance

HBIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HBIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+35.3%

Float: +78.3% of shares outstanding

Insider ownership

+6.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

HBIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.5

Neutral momentum band

Price vs 200-day MA

+23.6%

50/200-day relationship not available

Beta (5Y)

1.57

More volatile than the market

Sharpe ratio

1.08

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HBIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current HBIO stock rating?

Harvard Bioscience, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full HBIO analysis?

The full report lives at /stocks/HBIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for HBIO?

The latest report frames HBIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the HBIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.